Effect of levetiracetam and oxcarbazepine on 4-year fragility fracture risk among prepubertal and pubertal children with epilepsy.

Daniel G WhitneyMichelle S CairdEdward A HurvitzChamith S RajapakseErin M Fedak Romanowski

Published in: Epilepsia (2021)

Initiating OXC, but not LEV, therapy among 4-13-year-olds with epilepsy is associated with an elevated risk of fragility fracture. Studies are needed to determine whether these children could benefit from adjunct bone fragility therapies.

Keyphrases

young adults
bone mineral density
stem cells
mesenchymal stem cells
bone loss
smoking cessation
growth hormone